Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hengqing II prescription is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Shanghai Sixth People's Hospital for the treatment of Alzheimer's disease. It is specifically designed to address the TCM syndrome of kidney deficiency, phlegm, and blood stasis. The prescription is currently being evaluated in interventional clinical trials (e.g., ChiCTR2000036082) that utilize systems biology approaches—including metabolomics, transcriptomics, and proteomics—to identify therapeutic biomarkers and assess clinical efficacy in comparison to standard treatments like donepezil (Aricept) and placebo. The formulation aims to improve cognitive and functional outcomes by addressing the underlying TCM pathological mechanisms associated with neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hengqing II prescription.